Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 14.08M shares rose 29.8% year over year, behind the +49.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 10.7% from the prior quarter. Over 3 fiscal years it compounded at +46.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +29.8% toward the trailing-twelve-month pace of +49.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
14.08M+10.7% QoQ
Last fiscal yearDec 2025
12.72M+69.8% YoY
LTMMar 2026
13.17M+49.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.8%——
1 year+69.8%——
3-year CAGR+46.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
12.72M USD
Year-over-year change
+69.8%
4-year CAGR
+35.7%

Weighted Avg Shares (Diluted) vs competitors

How ATRA compares with its peers on the latest reported figures

  • ATRA's LTM Mar 2026 weighted avg shares (diluted) of 13.17M shares is the 9th highest of the 11 companies compared; the peer median is 52.85M shares.
  • Its year-over-year change of +49.9% is the 2nd highest of 11, against a peer median of +5.3%.
  • Over three fiscal years its annual growth of +46.1% compares with a peer median of +16.5%.
ATRA Competitors Peer median
Weighted Avg Shares (Diluted) for ATRA and competitors
Company Period LTM YoY 3-year CAGR
CNTXContext Therapeutics Inc.LTM Mar 202694.36M +30.6%+81.3%
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.7%+1.5%
IFRXInflaRx N.V.LTM Mar 202668.86M +14.8%+15.0%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
ORMPOramed Pharmaceuticals Inc.LTM Mar 202642.44M +3.8%+2.8%
COYACoya Therapeutics, Inc.LTM Mar 202616.73M +5.9%+18.9%
CSBRChampions Oncology, Inc.LTM Jan 202613.97M -0.2%+0.3%
ATRAAtara Biotherapeutics, Inc.LTM Mar 202613.17M +49.9%+46.1%
CLNNClene Inc.LTM Mar 202610.33M +43.6%+44.6%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding ATRA) 52.85M+5.3%+16.5%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.34M63.57M8.57M128.94M120.77M
Cost of Revenue282M269.99M8.89M21.01M21.21M
Gross Profit(261.66M)(206.42M)(313K)107.93M99.56M
Gross Margin-1286.4%-324.7%-3.7%83.7%82.4%
Research & Development282M272.53M224.79M151.48M37.45M
Selling, General & Admin78.8M68.13M50.91M39.89M26.25M
Operating Expenses78.8M74.1M275.69M191.37M63.7M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.12M
EBITDA(330.75M)(222.26M)(266M)(75.75M)38.63M
EBITDA Margin-1626.1%-349.6%-3102.7%-58.7%32.0%
Operating Income(340.46M)(280.51M)(276.01M)(83.44M)35.86M
Operating Margin-1673.9%-441.2%-3219.5%-64.7%29.7%
Interest Income367K3.06M5.43M2.11M683K
Interest Expense0373K5.29M4.62M3.79M
Other Income / Expenses367K52.22M(105K)(1.98M)(3.14M)
Income Before Tax(340.1M)(228.29M)(276.11M)(85.42M)32.72M
Pre-Tax Margin-1672.1%-359.1%-3220.7%-66.2%27.1%
Income Tax Expense46K12K15K(12K)31K
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Net Margin-1672.3%-359.1%-3220.9%-66.2%27.1%
EPS (Basic)(90.78)(55.96)(65.18)(11.41)2.61
EPS (Diluted)(90.78)(55.96)(65.18)(11.41)2.57
Weighted Avg Shares3.75M4.08M4.24M7.49M12.54M
Weighted Avg Shares (Diluted)3.75M4.08M4.24M7.49M12.72M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.